COURSE:
NR546 – Advanced Pharmacology: Psychopharmacology
Preparing the Assignment
Follow these guidelines when completing each component of the assignment. Contact your course faculty if you have questions.
General Instructions
Download the Week 6 Medication Table. and complete the required information using the template.
Include the following sections (detailed criteria listed below and in the grading rubric)
- For each medication listed, complete the following:
- Provide indication, target symptoms, and affected neurotransmitters.
- Include half-life and CYP 450 enzyme information.
- List notable side effects and link notable side effects to the associated pathway or neurotransmitter.
- List Initial Dosing Considerations and specific lifespan considerations (age, pregnancy, breastfeeding).
Solution
| Drug Name
|
Indication
Neurotransmitter(s) Affected Target Symptoms |
Half-life (T1/2), Metabolism (CYP 450 enzyme) | Notable Side Effects (link to NT or affected brain circuit) | Initial Dosing Considerations
Specific lifespan considerations (age, pregnancy, breastfeeding) |
| Buprenorphine (Subutex) | Indication:
· Maintenance treatment of opioid dependence · Maintenance treatment of opioid dependence in patients who have achieved and sustainced prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine containing product · Moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine containing product, followed by dose adjustment for a minimum of 7 days Neurotransmitters: · Mu opioid receptor partial agonist · Antagonist at the kappa opioid receptor Target symptoms: Opioid dependence |
Half-life:
24-42 hours CYP450: CYP3A4 |
· Headache,
constipation, nausea · Oral hypoesthesia, glossodynia · Orthostatic hypotension · Implant specific: insertion site pain, pruritis, erythema · Respiratory depression · Hepatotoxicity |
Initial dosing:
Day 1: 8 mg Day 2: 12-16 mg Days 3-7: Increase in increments of 4 mg, maximum 32 mg Considerations: · Use with caution in elderly and those with cardiac impairment · May be preferable to methadone in pregnant women · Neonatal withdrawal may occur · Drug is found in breast milk, recommended to DC drug or bottle feed · Safety and efficacy has not been established for children and adolescents |
……………………………………………..$5